132 related articles for article (PubMed ID: 16645546)
1. An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugs.
van Maarseveen NM; de Jong D; Boucher CA; Nijhuis M
J Acquir Immune Defic Syndr; 2006 Jun; 42(2):162-8. PubMed ID: 16645546
[TBL] [Abstract][Full Text] [Related]
2. Evolution of the human immunodeficiency virus type 1 protease: effects on viral replication capacity and protease robustness.
Capel E; Martrus G; Parera M; Clotet B; Martínez MA
J Gen Virol; 2012 Dec; 93(Pt 12):2625-2634. PubMed ID: 22933665
[TBL] [Abstract][Full Text] [Related]
3. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.
van Maarseveen NM; Wensing AM; de Jong D; Taconis M; Borleffs JC; Boucher CA; Nijhuis M
J Infect Dis; 2007 Feb; 195(3):399-409. PubMed ID: 17205479
[TBL] [Abstract][Full Text] [Related]
4. Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity.
van Maarseveen NM; Andersson D; Lepšík M; Fun A; Schipper PJ; de Jong D; Boucher CA; Nijhuis M
Retrovirology; 2012 Apr; 9():29. PubMed ID: 22462820
[TBL] [Abstract][Full Text] [Related]
5. Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection.
Simon V; Padte N; Murray D; Vanderhoeven J; Wrin T; Parkin N; Di Mascio M; Markowitz M
J Virol; 2003 Jul; 77(14):7736-45. PubMed ID: 12829813
[TBL] [Abstract][Full Text] [Related]
6. The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication.
Margerison ES; Maguire M; Pillay D; Cane P; Elston RC
J Antimicrob Chemother; 2008 Apr; 61(4):786-91. PubMed ID: 18252693
[TBL] [Abstract][Full Text] [Related]
7. Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant HIV-1 variants under drug pressure.
Suñé C; Brennan L; Stover DR; Klimkait T
Clin Microbiol Infect; 2004 Feb; 10(2):119-26. PubMed ID: 14759236
[TBL] [Abstract][Full Text] [Related]
8. Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.
Pingen M; Wensing AM; Fransen K; De Bel A; de Jong D; Hoepelman AI; Magiorkinis E; Paraskevis D; Lunar MM; Poljak M; Nijhuis M; Boucher CA;
Retrovirology; 2014 Nov; 11():105. PubMed ID: 25575025
[TBL] [Abstract][Full Text] [Related]
9. The HIV type 1 protease L10I minor mutation decreases replication capacity and confers resistance to protease inhibitors.
Flor-Parra F; Pérez-Pulido AJ; Pachón J; Pérez-Romero P
AIDS Res Hum Retroviruses; 2011 Jan; 27(1):65-70. PubMed ID: 21142921
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness.
Berkhout B
J Biomed Sci; 1999; 6(5):298-305. PubMed ID: 10494036
[TBL] [Abstract][Full Text] [Related]
11. In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385.
Yates PJ; Hazen R; St Clair M; Boone L; Tisdale M; Elston RC
Antimicrob Agents Chemother; 2006 Mar; 50(3):1092-5. PubMed ID: 16495277
[TBL] [Abstract][Full Text] [Related]
12. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.
Mammano F; Trouplin V; Zennou V; Clavel F
J Virol; 2000 Sep; 74(18):8524-31. PubMed ID: 10954553
[TBL] [Abstract][Full Text] [Related]
13. Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457).
Adamson CS; Waki K; Ablan SD; Salzwedel K; Freed EO
J Virol; 2009 May; 83(10):4884-94. PubMed ID: 19279107
[TBL] [Abstract][Full Text] [Related]
14. Quantitative SNP-detection method for estimating HIV-1 replicative fitness: application to protease inhibitor-resistant viruses.
Ibe S; Fujisaki S; Fujisaki S; Morishita T; Kaneda T
Microbiol Immunol; 2006; 50(10):765-72. PubMed ID: 17053312
[TBL] [Abstract][Full Text] [Related]
15. Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.
Ho SK; Coman RM; Bunger JC; Rose SL; O'Brien P; Munoz I; Dunn BM; Sleasman JW; Goodenow MM
Virology; 2008 Sep; 378(2):272-81. PubMed ID: 18599104
[TBL] [Abstract][Full Text] [Related]
16. Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure.
Boeri E; Gianotti N; Canducci F; Hasson H; Giudici B; Castagna A; Lazzarin A; Clementi M
AIDS Res Hum Retroviruses; 2003 Dec; 19(12):1151-3. PubMed ID: 14714567
[TBL] [Abstract][Full Text] [Related]
17. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1.
Myint L; Matsuda M; Matsuda Z; Yokomaku Y; Chiba T; Okano A; Yamada K; Sugiura W
Antimicrob Agents Chemother; 2004 Feb; 48(2):444-52. PubMed ID: 14742193
[TBL] [Abstract][Full Text] [Related]
18. Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection.
Leigh Brown AJ; Frost SD; Good B; Daar ES; Simon V; Markowitz M; Collier AC; Connick E; Conway B; Margolick JB; Routy JP; Corbeil J; Hellmann NS; Richman DD; Little SJ
J Virol; 2004 Mar; 78(5):2242-6. PubMed ID: 14963120
[TBL] [Abstract][Full Text] [Related]
19. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
[TBL] [Abstract][Full Text] [Related]
20. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.
Nijhuis M; Schuurman R; de Jong D; Erickson J; Gustchina E; Albert J; Schipper P; Gulnik S; Boucher CA
AIDS; 1999 Dec; 13(17):2349-59. PubMed ID: 10597776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
